Nektar Therapeutics starts Phase 3 ZENITH-AD trials of rezpegaldesleukin for atopic dermatitis
Nektar Therapeutics has initiated the first two studies in a 1,530-patient Phase 3 programme evaluating rezpegaldesleukin in adolescents and adults with moderate-to-severe atopic dermatitis, beginning the pivotal test of whether regulatory T-cell stimulation can compete with established eczema biologics and oral medicines. ZENITH AD-1 and ZENITH AD-2 will each enroll approximately 510 patients who have
